307 related articles for article (PubMed ID: 34220335)
1. IgG4 as a Biomarker in Graves' Orbitopathy.
Olejarz M; Szczepanek-Parulska E; Dadej D; Sawicka-Gutaj N; Domin R; Ruchała M
Mediators Inflamm; 2021; 2021():5590471. PubMed ID: 34220335
[TBL] [Abstract][Full Text] [Related]
2. Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy.
Yu SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Thyroid; 2017 Sep; 27(9):1185-1193. PubMed ID: 28805160
[TBL] [Abstract][Full Text] [Related]
3. IgG4 serum levels in Graves' orbitopathy.
Comi S; Lanzolla G; Cosentino G; Maglionico MN; Posarelli C; Menconi F; Santini F; Elisei R; Marinò M
J Endocrinol Invest; 2024 Jul; 47(7):1711-1717. PubMed ID: 38127192
[TBL] [Abstract][Full Text] [Related]
4. Exophthalmos in a young woman with no graves' disease - a case report of IgG4-related orbitopathy.
Erdei A; Steiber Z; Molnar C; Berenyi E; Nagy EV
BMC Ophthalmol; 2018 Jan; 18(1):5. PubMed ID: 29329570
[TBL] [Abstract][Full Text] [Related]
5. [Autoantibodies, immunoglobulins and cytokine profile in patients with graves' disease and Graves' orbitopathy].
Sviridenko NY; Bessmertnaya EG; Belovalova IM; Mikheenkov AA; Sheremeta MS; Nikankina LV; Malysheva NM
Probl Endokrinol (Mosk); 2020 Oct; 66(5):15-23. PubMed ID: 33369369
[TBL] [Abstract][Full Text] [Related]
6. Serum Immunoglobulin G4 levels are elevated in patients with Graves' ophthalmopathy.
Bozkirli E; Bakiner OS; Ersozlu Bozkirli ED; Eksi Haydardedeoglu F; Sizmaz S; Torun AI; Ertorer ME
Clin Endocrinol (Oxf); 2015 Dec; 83(6):962-7. PubMed ID: 25400133
[TBL] [Abstract][Full Text] [Related]
7. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
Marinò M; Rotondo Dottore G; Ionni I; Lanzolla G; Sabini E; Ricci D; Sframeli A; Mazzi B; Menconi F; Latrofa F; Vitti P; Marcocci C; Chiovato L
J Endocrinol Invest; 2019 Apr; 42(4):471-480. PubMed ID: 30132285
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of serum immunoglobulin G4 in glucocorticoid therapy of Graves' ophthalmopathy.
Li Y; Luo B; Zhang J; Zhou X; Shao S; Xu W; Yang Y; Yuan G
Clin Endocrinol (Oxf); 2021 Oct; 95(4):657-667. PubMed ID: 33938028
[TBL] [Abstract][Full Text] [Related]
9. Modulating gut microbiota in a mouse model of Graves' orbitopathy and its impact on induced disease.
Moshkelgosha S; Verhasselt HL; Masetti G; Covelli D; Biscarini F; Horstmann M; Daser A; Westendorf AM; Jesenek C; Philipp S; Diaz-Cano S; Banga JP; Michael D; Plummer S; Marchesi JR; Eckstein A; Ludgate M; Berchner-Pfannschmidt U;
Microbiome; 2021 Feb; 9(1):45. PubMed ID: 33593429
[TBL] [Abstract][Full Text] [Related]
10. High IgG4 serum concentration is associated with active Graves orbitopathy.
Olejarz M; Szczepanek-Parulska E; Ostałowska-Klockiewicz A; Antosik P; Sawicka-Gutaj N; Helak-Łapaj C; Stopa M; Ruchala M
Front Endocrinol (Lausanne); 2023; 14():1083321. PubMed ID: 36936165
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum immunoglobulin G4 levels in patients with Graves' disease and their clinical implications.
Takeshima K; Inaba H; Furukawa Y; Nishi M; Yamaoka H; Miyamoto W; Ota T; Doi A; Kawashima H; Ariyasu H; Wakasaki H; Furuta H; Nakao T; Sasaki H; Akamizu T
Thyroid; 2014 Apr; 24(4):736-43. PubMed ID: 24256421
[TBL] [Abstract][Full Text] [Related]
12. Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves' orbitopathy.
Nicolì F; Lanzolla G; Mantuano M; Ionni I; Mazzi B; Leo M; Sframeli A; Posarelli C; Maglionico MN; Figus M; Nardi M; Marcocci C; Marinò M
J Endocrinol Invest; 2021 Mar; 44(3):581-585. PubMed ID: 32648002
[TBL] [Abstract][Full Text] [Related]
13. [Clinical and immunological predictors of Graves' orbitopathy after radioiodine therapy of Graves' disease].
Sheremeta MS; Bessmertnaya EG; Elfimova AR; Babaeva DM; Belovalova IM; Sviridenko NY
Probl Endokrinol (Mosk); 2023 Nov; 69(5):16-24. PubMed ID: 37968948
[TBL] [Abstract][Full Text] [Related]
14. Comparative assessment of Graves' disease and main extrathyroidal manifestation, Graves' ophthalmopathy, by non-targeted metabolite profiling of blood and orbital tissue.
Ji DY; Park SH; Park SJ; Kim KH; Ku CR; Shin DY; Yoon JS; Lee DY; Lee EJ
Sci Rep; 2018 Jun; 8(1):9262. PubMed ID: 29915201
[TBL] [Abstract][Full Text] [Related]
15. Genetic immunization with mouse thyrotrophin hormone receptor plasmid breaks self-tolerance for a murine model of autoimmune thyroid disease and Graves' orbitopathy.
Schlüter A; Horstmann M; Diaz-Cano S; Plöhn S; Stähr K; Mattheis S; Oeverhaus M; Lang S; Flögel U; Berchner-Pfannschmidt U; Eckstein A; Banga JP
Clin Exp Immunol; 2018 Mar; 191(3):255-267. PubMed ID: 29058307
[TBL] [Abstract][Full Text] [Related]
16. Nicotinamide phosphoribosyltransferase leukocyte overexpression in Graves' opthalmopathy.
Sawicka-Gutaj N; Budny B; Zybek-Kocik A; Sowiński J; Ziemnicka K; Waligórska-Stachura J; Ruchała M
Endocrine; 2016 Aug; 53(2):497-504. PubMed ID: 26767650
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a tear protein biomarker panel differentiating between Graves' disease with or without orbitopathy.
Aass C; Norheim I; Eriksen EF; Børnick EC; Thorsby PM; Pepaj M
PLoS One; 2017; 12(4):e0175274. PubMed ID: 28419103
[TBL] [Abstract][Full Text] [Related]
18. Ocular Manifestations and Clinical Implications of Serum Immunoglobulin G4 Levels in Graves' Ophthalmopathy Patients.
Luo B; Yuan X; Wang W; Zhang J; Liu R; Hu W; Qi X; Xiang N; Chen L
Ocul Immunol Inflamm; 2022 Apr; 30(3):580-587. PubMed ID: 33054491
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of IL-29 in Euthyroid Patients with Graves' Orbitopathy: A Preliminary Study.
Falkowski B; Szczepanek-Parulska E; Sawicka-Gutaj N; Krygier A; Ruchala M
Mediators Inflamm; 2020; 2020():4748612. PubMed ID: 32694926
[TBL] [Abstract][Full Text] [Related]
20. Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves' Disease: results of a pilot study.
Lanzolla G; Ricci D; Nicolì F; Sabini E; Sframeli A; Brancatella A; Mantuano M; Dottore GR; Bucci I; Figus M; Nardi M; Latrofa F; Marcocci C; Marinò M
J Endocrinol Invest; 2020 Dec; 43(12):1759-1768. PubMed ID: 32583374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
